Clostridioides difficile infection (CDI) is an opportunistic infection of the gastrointestinal tract, commonly associated with antibiotic administration, that afflicts almost 500 000 people yearly only in the United States. CDI incidence and recurrence is increased in inflammatory bowel disease (IBD) patients. Omilancor is an oral, once daily, first-in-class, gut-restricted, immunoregulatory therapeutic in clinical development for the treatment of IBD.
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
New Data Presented at IMMUNOLOGY2026 Shows LANCL2 Medicines in Clinical Development for IBD Can Provide Protection from Asthma
NImmune Biopharma, Inc is pleased to share the release of exciting new data on the efficacy of LANCL2 medicines in treating inflammatory diseases and their immunometabolic mechanisms of action at The American Association of Immunologists Annual Meeting,...
